Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MDCX | 8-K | neutral | 3/10 | Medicus Pharma Ltd. filed an 8-K reporting a 1-for-50 reverse stock split (share consolidation) effective October 12, 20 | Oct 16, 2026 |
| ALEC | 424B5 | bearish | 6/10 | Alector is offering 36,600,000 shares of common stock at $2.05 per share, expecting net proceeds of approximately $70.2 | Oct 16, 2026 |
| CTY | 424B4 | neutral | 5/10 | City Therapeutics priced its IPO of 11,111,111 shares at $18.00 per share, raising approximately $200 million in gross p | Oct 16, 2026 |
| ALEC | 8-K | bearish | 7/10 | Alector priced a dilutive underwritten offering of 36.6M shares at $2.05/share, raising ~$75M in gross proceeds. The off | Oct 16, 2026 |
| CALC | 8-K | bearish | 5/10 | CFO Stephen Bardin resigned effective after the Q3 2026 10-Q filing to pursue another opportunity, with no disagreement | Oct 16, 2026 |
| TCRX | 8-K | neutral | 2/10 | Two board members, Garry Nicholson and Gabriela Gruia, M.D., resigned from TScan Therapeutics' board effective October 1 | Oct 16, 2026 |
| ELVN | 3 | neutral | 2/10 | Kristine Ball filed a Form 3 initial statement of beneficial ownership with Enliven Therapeutics, Inc. (ELVN) after beco | Oct 16, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined $1.38M in open-market sales, with the CEO exercising and immedi | Oct 16, 2026 |
| NVAX | SC 13G | neutral | 4/10 | Shah Capital Management, a North Carolina-based investment adviser, filed a Schedule 13G disclosing a passive 6.39% bene | Oct 16, 2026 |
| TLSA | 6-K | bearish | 6/10 | Tiziana Life Sciences reported H1 2026 interim results showing a deepened net loss of $12.4 million (vs. $5.3 million in | Oct 16, 2026 |
| MDCX | SC 13G/A | neutral | 3/10 | Kenneth R. Melani and Velocity Fund Partners, LP filed a Schedule 13G/A disclosing a combined 3.6% stake (3,248,741 comm | Oct 16, 2026 |
| ADRX | SC 13G | neutral | 3/10 | LAV Biosciences Fund V, L.P. and affiliated entities (LAV Fund VI, L.P., LAV Fund VI Opportunities, L.P., and Yi Shi) fi | Oct 16, 2026 |
| GILD | CLUSTER | neutral | 2/10 | Two GILD C-suite executives (CFO and Chief Communications & Corporate Affairs Officer) each sold $469K worth of stock on | Oct 16, 2026 |
| TOMZ | 8-K | neutral | 2/10 | TOMI Environmental Solutions appointed Niroshan Srirathan as permanent CFO, effective October 11, 2026, after he served | Oct 16, 2026 |
| OCUL | 8-K | neutral | 2/10 | Chief Strategy Officer Sanjay Nayak resigned effective October 16, 2026 to become CEO of a private company. The departur | Oct 16, 2026 |
| QUCY | 8-K | neutral | 2/10 | Quantum Cyber N.V. appointed retired Major General Alberto C. Rosende as an independent director and committee member, e | Oct 16, 2026 |
| NVAX | SC 13D/A | bearish | 6/10 | Shah Capital Management filed Amendment No. 8 to its Schedule 13D, reporting a reduction in its aggregate beneficial own | Oct 16, 2026 |
| ZBIO | PRESS-RELEASE | neutral | 2/10 | Zenas BioPharma granted 74,900 RSUs to new hires as an inducement material to employment, vesting over four years. This | Oct 16, 2026 |
| BEAM | 144 | neutral | 3/10 | John M. Evans, an officer and director of Beam Therapeutics, filed a Form 144 notice to sell 25,000 common shares with a | Oct 16, 2026 |
| AIMD | 8-K | neutral | 2/10 | Ainos, Inc. filed an 8-K on October 14, 2026, adopting a classified board structure via Second Amended and Restated Byla | Oct 16, 2026 |
| AIBT | 8-K | neutral | 4/10 | Aibotics completed the acquisition of PlayJamaica's NovaCore Labs robotics, drone, AI, and mapping assets for $225,000 i | Oct 16, 2026 |
| BGMS | 8-K | neutral | 2/10 | Bio Green Med Solution, Inc. declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Pr | Oct 16, 2026 |
| VIVS | 8-K | bearish | 5/10 | VivoSim Labs' wholly-owned subsidiary Organovo, Inc. amended its lease to reduce office space by vacating Suite 202 (2,8 | Oct 16, 2026 |
| MAZE | 8-K | neutral | 4/10 | Maze Therapeutics entered into an exchange agreement with Frazier Life Sciences funds to exchange 2,776,007 shares of co | Oct 16, 2026 |
| KRRO | PRESS-RELEASE | neutral | 2/10 | Korro Bio granted non-statutory stock options to two new employees as an inducement to employment, covering 4,000 shares | Oct 16, 2026 |
| VTRS | PRESS-RELEASE | bullish | 6/10 | Viatris received FDA approval for RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in ad | Oct 16, 2026 |
| CMND | 6-K | bearish | 6/10 | Clearmind Medicine issued a notice to CLA Investors to sell $2,000,000 in convertible promissory notes at a 10% discount | Oct 16, 2026 |
| ASND | 6-K | bullish | 7/10 | Ascendis Pharma announced that the EMA's CHMP adopted a positive opinion recommending EU marketing authorization for Tra | Oct 16, 2026 |
| QURE | SC 13G/A | neutral | 3/10 | JPMorgan Chase & Co. filed an amended Schedule 13G disclosing beneficial ownership of 5,951,794 ordinary shares of uniQu | Oct 16, 2026 |
| RTSN | SC 13G | neutral | 3/10 | PVG Asset Management Corp disclosed a passive 8.3% stake in Retension Pharmaceuticals via a Schedule 13G filed October 1 | Oct 16, 2026 |